HOME >> BIOLOGY >> NEWS
'Madagascar Declaration' focuses African development policies on value of nature

Antananarivo, Madagascar (June 24, 2006) Ambitious goals for reducing poverty and disease in Africa are unreachable without radical changes that make biodiversity and its socioeconomic value the foundation for development policies, a global environmental conference concluded Saturday.

The symposium organized by Conservation International, titled "Defying Nature's End: The African Context," produced a five-page "Madagascar Declaration" that challenges traditional aid and development models for the world's poorest and most disease-ridden continent.

Among its conclusions, the declaration states that African states and international development agencies such as the United Nations and World Bank should recognize that conserving Africa's rich biodiversity is fundamental to achieving sustainable development and reducing poverty.

Noting that biodiversity provides clean air and water, food, natural resources, soil regeneration, pollination and other so-called ecosystem services, the declaration calls such natural benefits essential to any chance for African nations to achieve the Millennium Development Goals set by the United Nations in 2000 to achieve significant progress in reducing poverty worldwide by 2015.

"We believe these goals will not be achieved without a radical change in how the environment and biodiversity are addressed in national development plans and in foreign assistance strategies and investments," the declaration states.

It received immediate endorsement from dignitaries attending the symposium's final ceremony, including Prime Minister Jacques Sylla of Madagascar and Jeffrey Sachs, head of the U.N. Millennium Project. ''I think you've gotten it just right, and I'm very proud to associate the Millennium Project with the Madagascar Declaration," Sachs said. "There will be no escape from hunger, poverty and disease if ecosystem degradation continues at the current rate."

The five-day conferenc
'"/>

Contact: Tom Cohen
tcohen@conservation.org
202-912-1532
Conservation International
24-Jun-2006


Page: 1 2 3

Related biology news :

1. New UD tissue-engineering research focuses on vocal cords
2. Chemical Society Boston meeting, Aug. 19-23, focuses on health, wellness, energy, environment
3. June 2007 issue of the Journal of Ultrasound in Medicine focuses on contrast-enhanced ultrasound
4. Study focuses on only carnivore with fingerprints
5. Researcher focuses on pros, cons of antioxidants from fruits and vegetables
6. New text focuses on microbes in the mouth
7. Report focuses on the role good microbes play in future medicine
8. Upcoming NJIT conference focuses on Hurricane Katrina, technology, more
9. Microbiology meeting focuses on myriad of topics
10. Special issue of the Journal of Industrial Ecology focuses on eco-efficiency
11. New partnership focuses on prostate cancer diagnostics

Post Your Comments:
(Date:10/18/2014)... suspected genetic conditions, a certain type of exome sequencing ... than traditional molecular diagnostic methods, according to a study ... released to coincide with the American Society of Human ... protein­coding region of the genome (the complete set of ... organism), has been rapidly applied in research settings and ...
(Date:10/17/2014)... release is available in German . ... of sperms every day in order to reproduce? And why ... the topic of the latest issue of the research journal ... The evolutionary biologist Steven Ramm from Bielefeld University Bielefeld has ... is not unusual for a female to copulate with several ...
(Date:10/17/2014)... To date, antidotes ... doctors are often limited to supportive therapy such as induced ... of drugs involved. So what can be done if a ... professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences at ... "The task was to develop an agent that could eliminate ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Sperm wars 2Emergency aid for overdoses 2Emergency aid for overdoses 3
(Date:10/22/2014)... Oct. 22, 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, announced today that ... Notice of Allowance for a composition of matter patent ... difficile program, SYN-004. This is Synthetic Biologics, first ... U.S. and adds to the Company,s extensive C. ...
(Date:10/22/2014)... and HONG KONG , Oct. ... disease therapeutics enterprise, announced today that rare disease expert ... as vice president, research. Dr. McKew brings more than ... leadership positions at the National Institutes of Health, Wyeth ... by Wyeth). Dr. McKew will lead aTyr,s efforts to expand ...
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
(Date:10/20/2014)... BOSTON , Oct. 20, 2014 ... commercialization company tackling big healthcare problems, announced today ... investment round, with participation from Invesco Perpetual, a ... be used to drive PureTech,s existing pipeline forward ... technologies. "PureTech has the scientific creativity to really ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
Cached News: